Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.44 |
| ▸ | CNR2 | P34972 | 17/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25393933 | 0.91 | CNR1 (0.46) | CNR1CNR2EPHX2FEN1 | |
| SCHEMBL30302005 | 0.89 | EPHX2 (0.44) | EPHX2 | |
| SCHEMBL30555429 | 0.88 | CNR2 (0.44) | CNR1CNR2 | |
| SCHEMBL25393523 | 0.86 | EPHX2 (0.48) | CNR1EPHX2 | |
| SCHEMBL25392115 | 0.84 | EPHX2 (0.39) | CNR1CNR2EPHX2 | |
| SCHEMBL25393273 | 0.84 | EPHX2 (0.50) | CNR1CNR2EPHX2 | |
| SCHEMBL28673163 | 0.83 | CNR2 (0.47) | CNR1CNR2 | |
| SCHEMBL12183597 | 0.81 | CNR2 (0.46) | CNR1CNR2FEN1 | |
| SCHEMBL25394559 | 0.81 | CNR1 (0.40) | CNR1CNR2EPHX2FEN1 | |
| SCHEMBL28702300 | 0.81 | CACNA2D1 (0.45) | CNR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| CN-113993587-A | Thiazole derivatives as protein secretion inhibitors | 科智生命科学公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | CNR1 4399/4885CNR2 4727/4885EPHX2 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.